Table 2.

Treatment administration

Interim populationOverall population
n = 34N = 86
Group 1Group 2Group 1Group 2
n = 17n = 17an = 40n = 46a
Number of cycles Median (range)22 (4–38)12 (0–30)14.5 (3–38)13.5 (0–40)
Duration of treatment (mo) Median (range)14 (1–28)6.5 (0–25)7 (1–28)7.0 (0–25)
Dose per cycle (cycles 1 to 4), median (range)
 Bolus 5FU (mg/m2)392.9 (0; 410.2)398.9 (0–419)396.1 (0–411.0)394.9 (0–419)
 IV 5FU (mg/m2)2,357.4 (1633.4; 2474.0)2,398.8 (0–2493.1)2,389.4 (1633.4–2474.0)2,393.1 (0–2493.1)
 Irinotecan (mg/m2)255.2 (175.6; 264.3)260.0 (0–270.6)257.8 (162.8–264.3)2,56.2 (0–270.6)
 Bevacizumab (mg/kg)5.0 (3.8; 5.0)4.9 (0–5.3)5.0 (3.8–5.2)5.0 (0–5.4)
  • NOTE: Group 1: UGTA1*1/UGTA1*1; Group 2: UGT1A1*1/UGT1A1*28.

    a1 patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion.